drugset / Trial / NCT06974565

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

NCT06974565

Phase 1 Completed 16 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.

Timeline

Start
2025-05-12
Primary completion
2025-07-18
Completion
2025-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2389 Small molecule Oral
Subject Quinidine Small molecule Oral

Indications